Clearmind reports positive safety, tolerability in CMND-100 Phase I/II trial Part A dose escalation
CMND•CMND-100 Phase I/II trial Part A shows positive safety results
Clearmind Medicine reported positive safety results from Part A of its FDA-regulated Phase I/II trial of CMND-100 for Alcohol Use Disorder.
Results have now been presented, covering the full planned dose-escalation in healthy volunteers.
The study met its primary safety and tolerability endpoint, with no serious adverse events reported.
The outcome supports continued clinical development, with the company preparing to move into later stages that include dosing AUD patients.
